BioSpace News Archive

Akebia Therapeutics , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that its President and Chief Executive Officer, John P. Butler , will participate in the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20

Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that President Rajiv Malik and Chief Financial Officer Ken Parks will present at the BofA Securities Virtual Health Care Conference 2020 on Thursday, May 14, 2020 at 3:40 p.m. ET.

Myosrens to host conference call today

Results Suggest Highly Effective Method to Treat Ventricular Tachycardia, a Leading Cause of Sudden Cardiac Death

American Renal Associates Holdings, Inc., a leading kidney care and dialysis provider focused on partnering with local nephrologists, announced that Christopher J. Hocevar has been appointed to join the Company’s board of directors and that Steve M. Silver, who has served on ARA’s board for a number of years, has transitioned his board seat to Jeremy W. Gelber, M.D.

Meeting to Be Held on Friday, May 29, 2020 in Virtual-Only Format

jCyte Inc., a biotech company dedicated to improving the lives of patients with rare degenerative retinal diseases, today announced it has entered into a licensing agreement with Santen Pharmaceutical to develop and commercialize its first-in-class, investigational therapy, jCell, outside the U.S., in regions including Europe, Asia and Japan.

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in upcoming investor conferences

- Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv mecarbil, a novel selective cardiac myosin activator, also known as a cardiac myotrope, 1 being developed for the potential treatment of chronic heart failure with reduced ejection fraction (HFrEF). Fast Track designation may p

Amgen (NASDAQ:AMGN) and Cytokinetics, Incorporated (NASDAQ:CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for omecamtiv m